First Chinese patent for GILUPI was granted in March 2016
GILUPI detection device for in vivo and/or in vitro enrichment of sample material
(PresseBox) - GILUPI GmbH announced today, that the company received the first Chinese patent protecting the unique and innovative GILUPI technology.
The patent (ZL201080027208.2) titles ?detection device for in vivo and/or in vitro enrichment of sample material? describes a functionalized structured medical wire for the accumulation of sample material. The device comprising a biocompatible polymer and a functional surface equipped with detection receptors which for example enables the isolation of cells directly from the blood of patients (in vivo). This patented technology is already being used in clinical settings on national and international level.
The recently received patent is an important supplementation of GILUPI`s intellectual property portfolio. Thus, the company has a broad and strong intellectual property position required to run the GILUPI businesses. GILUPI has filed further patent applications that are currently subject to examination procedures for a number of inventions, hence further granted patents will follow soon.
GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.
Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.
For further information visit www.gilupi.com
GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.
Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.
For further information visit www.gilupi.com
Datum: 06.07.2016 - 10:03 Uhr
Sprache: Deutsch
News-ID 481706
Anzahl Zeichen: 2163
contact information:
Town:
Potsdam
Kategorie:
Handcrafts
Diese Pressemitteilung wurde bisher 1277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"First Chinese patent for GILUPI was granted in March 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
GILUPI GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
